These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29124934)

  • 21. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantum Mechanics/Molecular Mechanics Studies of the Mechanism of Cysteine Proteases Inhibition by Dipeptidyl Nitroalkenes.
    Arafet K; González FV; Moliner V
    Chemistry; 2020 Feb; 26(9):2002-2012. PubMed ID: 31692123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A survey of calpain inhibitors.
    Donkor IO
    Curr Med Chem; 2000 Dec; 7(12):1171-88. PubMed ID: 11032966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors.
    Zhang Y; Jung SY; Jin C; Kim ND; Gong P; Lee YS
    Bioorg Med Chem Lett; 2009 Jan; 19(2):502-7. PubMed ID: 19041242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calpain-1 inhibitors for selective treatment of rheumatoid arthritis: what is the future?
    Miller DJ; Adams SE; Hallett MB; Allemann RK
    Future Med Chem; 2013 Nov; 5(17):2057-74. PubMed ID: 24215346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irreversible caspase inhibitors: tools for studying apoptosis.
    Wu JC; Fritz LC
    Methods; 1999 Apr; 17(4):320-8. PubMed ID: 10196103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of a QM/MM-based FEP method to evaluate the anomalous hydration behavior of simple alkyl amines and amides: application to the design of FBPase inhibitors for the treatment of type-2 diabetes.
    Reddy MR; Singh UC; Erion MD
    J Am Chem Soc; 2011 Jun; 133(21):8059-61. PubMed ID: 21545145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naphthoquinones as Covalent Reversible Inhibitors of Cysteine Proteases-Studies on Inhibition Mechanism and Kinetics.
    Klein P; Barthels F; Johe P; Wagner A; Tenzer S; Distler U; Le TA; Schmid P; Engel V; Engels B; Hellmich UA; Opatz T; Schirmeister T
    Molecules; 2020 Apr; 25(9):. PubMed ID: 32354191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental Manipulation of Calpain Activity In Vitro.
    Kitagawa S
    Methods Mol Biol; 2019; 1915():209-218. PubMed ID: 30617806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel series of urea-based peptidomimetic calpain inhibitors.
    Sanders ML; Donkor IO
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1965-8. PubMed ID: 16412635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tripeptide analogues of MG132 as protease inhibitors.
    Pehere AD; Nguyen S; Garlick SK; Wilson DW; Hudson I; Sykes MJ; Morton JD; Abell AD
    Bioorg Med Chem; 2019 Jan; 27(2):436-441. PubMed ID: 30581047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.
    Brogi S; Ibba R; Rossi S; Butini S; Calderone V; Gemma S; Campiani G
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peptide alpha-keto ester, alpha-keto amide, and alpha-keto acid inhibitors of calpains and other cysteine proteases.
    Li Z; Patil GS; Golubski ZE; Hori H; Tehrani K; Foreman JE; Eveleth DD; Bartus RT; Powers JC
    J Med Chem; 1993 Oct; 36(22):3472-80. PubMed ID: 8230139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of peptidyl allyl sulfones as clan CA cysteine protease inhibitors.
    Fennell BD; Warren JM; Chung KK; Main HL; Arend AB; Tochowicz A; Götz MG
    J Enzyme Inhib Med Chem; 2013 Jun; 28(3):468-78. PubMed ID: 22380780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors.
    Lee KS; Seo SH; Lee YH; Kim HD; Son MH; Chung BY; Lee JY; Jin C; Lee YS
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2857-60. PubMed ID: 15911268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developments in the design and synthesis of calpain inhibitors.
    Neffe AT; Abell AD
    Curr Opin Drug Discov Devel; 2005 Nov; 8(6):684-700. PubMed ID: 16312145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advances in binding free energies calculations: QM/MM-based free energy perturbation method for drug design.
    Rathore RS; Sumakanth M; Reddy MS; Reddanna P; Rao AA; Erion MD; Reddy MR
    Curr Pharm Des; 2013; 19(26):4674-86. PubMed ID: 23260025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of human mu-calpain by conformationally constrained calpastatin peptides.
    Pfizer J; Assfalg-Machleidt I; Machleidt W; Schaschke N
    Biol Chem; 2008 Jan; 389(1):83-90. PubMed ID: 18095873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy.
    Lescop C; Herzner H; Siendt H; Bolliger R; Henneböhle M; Weyermann P; Briguet A; Courdier-Fruh I; Erb M; Foster M; Meier T; Magyar JP; von Sprecher A
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5176-81. PubMed ID: 16185867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors.
    Schiefer IT; Tapadar S; Litosh V; Siklos M; Scism R; Wijewickrama GT; Chandrasena EP; Sinha V; Tavassoli E; Brunsteiner M; Fa' M; Arancio O; Petukhov P; Thatcher GR
    J Med Chem; 2013 Aug; 56(15):6054-68. PubMed ID: 23834438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.